ASTRO 2025: Phase III Study of Hypofractionated, Dose Escalation Radiotherapy vs. Conventional Pelvic Radiation Therapy ...

The investigators hypothesized that the use of proton therapy for extended lymph node irradiation of the pelvic and ...

The 2025 ASTRO annual meeting featured a clinical trials session and a presentation by Dr. Amar Kishan discussing the primary ...

The co-primary endpoints were safety and efficacy: efficacy defined as ≥25% reduction in rectal rV70 in >75% of balloon ...

Dr. Justin Smith presented a secondary analysis of the TROG 08.03 RAVES trial evaluating quality of life after adjuvant or ...

No patients died of prostate cancer. The 5-year overall survival was 90%.

This was a single-center, retrospective analysis of 42 patients with MIBC who underwent TMT at the Moffitt Cancer Center ...

Dr. Jani highlighted the EMPIRE-1 trial, which evaluated the role of 18F-fluciclovine PET in guiding post-prostatectomy ...

Next, Dr. Mouw addressed the secondary analysis of the RAVES trial, which compared adjuvant and early salvage radiotherapy in ...

(UroToday.com The 2025 ASTRO annual meeting featured a prostate cancer session and a presentation by Dr. Beth Neilsen ...

The presence of adverse molecular features most closely correlated with genomic classifier scores, even within low grade tumors. There was an observed nearly 20-fold increase in the presence of ...

In intermediate risk prostate cancer patients randomized to short-term ADT and either 70 Gy or 76 Gy, testosterone recovery ...